Tiziana Life Sciences Ltd (TLSA)
| Bid | 1.58 |
| Market Cap | 92.51M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.88M |
| EPS (ttm) | -0.11 |
| PE Ratio (ttm) | -15.09 |
| Forward PE | -9.88 |
| Analyst | n/a |
| Ask | 1.78 |
| Volume | 389,126 |
| Avg. Volume (20D) | 341,651 |
| Open | 1.65 |
| Previous Close | 1.58 |
| Day's Range | 1.52 - 1.67 |
| 52-Week Range | 0.63 - 2.60 |
| Beta | 0.20 |
About TLSA
undefined
3 weeks ago · proactiveinvestors.com
Tiziana Life Sciences doses first MSA patient in new trial – ICYMITiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about the company's latest milestone: dosing the first patient in its Phase 2a clinical trial targeting multiple system at...
3 weeks ago · proactiveinvestors.com
Tiziana Life Sciences doses first patient in Phase 2a MSA trialTiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has enrolled and dosed the first participant in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System A...
4 weeks ago · proactiveinvestors.com
Tiziana Life Sciences Phase 2a multiple system atrophy study green-lit by FDATiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the US Food & Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its Phase 2a clinical trial of intranasal...
1 month ago · proactiveinvestors.com
Tiziana Life Sciences reports encouraging results from nasal Alzheimer's treatmentTiziana Life Sciences Ltd (NASDAQ:TLSA) said that its experimental nasal treatment for Alzheimer's disease showed promising results in a patient, helping reduce brain inflammation and possibly aiding ...
2 months ago · seekingalpha.com
Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis TargetingTiziana is developing foralumab, a fully human anti-CD3 monoclonal antibody, for non-active secondary progressive multiple sclerosis patients, with key data expected in 2026. A phase 2 trial of foralu...
2 months ago · proactiveinvestors.com
Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosingTiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center in New York City as part of its ongoing Phase 2 clinical ...